literature

HIV mutation literature information.

National survey of pre-treatment HIV drug resistance in Cuban patients.

PMID: 31479466 2019 PloS one

Table: M230L

Antiretroviral drug resistance mutations among patients failing first-line treatment in Hanoi, Vietnam.

PMID: 31190911 2019 Infection and drug resistance

Table: M230L

Emergence of HIV-1 drug resistance mutations in mothers on treatment with a history of prophylaxis in Ghana.

PMID: 30223845 2018 Virology journal

Result: Major DRAMs to NNRTIs seen in the Prophylaxis plus ART Group (Group 1) were K103 N, Y181C, M230 L and L100IL and the minor DRAMs to NNRTIs seen was A98G.

Result: The most common HIV-1 drug resistance associated mutations seen with the NNRTIs were K103 N, M230 L and A98G

Discussion: The presence of Y181C, M230 L and M230 LM posed resistance to all the NNRTIs used in the country for this group of people (the prophylaxis plus ART group).

Frequent cross-resistance to rilpivirine among subtype C HIV-1 from first-line antiretroviral therapy failures in South Africa.

PMID: 29566538 2018 Antiviral chemistry & chemotherapy

Method: Plasma samples contained a median of 3 [Q1-Q3: 2-4] NNRTI-associated drug resistance mutations which included A98G, L100I, K101E/H, K103N/S, V106M, V108I, E138A/K, V179D/E Y181C, Y188L/C, G190A, H221Y, P225H, F227L, and M230L.

Result: No other RPV-associated mutations in this sample set including K101E, E138A/K

Distinct Pattern of Thymidine Analogue Mutations with K65R in Patients Failing Tenofovir-Based Antiretroviral Therapy.

PMID: 29084434 2018 AIDS research and human retroviruses

Introduction: The most common mutations detected were Y181C, K103N, G190A, A98G, K101E, V108I, H221Y, M230L, and P225H.

Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128).

PMID: 28891788 2017 HIV clinical trials

Method: Primary NNRTI-R substitutions assessed were V90I, A98G, L100I, K101E/H/P, K103N/S, V106A/I/M, V108I, E138A/G/K/Q/R, V179D/F/L/T, Y181C/I/V, Y188C/H/L, G190A/E/Q/S, H221Y, P225H, F227C, and M230I/L in RT.

Early virological failure and HIV drug resistance in Ugandan adults co-infected with tuberculosis.

PMID: 28086929 2017 AIDS research and therapy

Table: M230L

HIV-1 drug-resistant mutations and related risk factors among HIV-1-positive individuals experiencing treatment failure in Hebei Province, China.

PMID: 28114955 2017 AIDS research and therapy

Result: One participant infected through heterosexual contact harbored dual mutations in NRTIs (T69N, M184V, and T215Y) and NNRTIs (K103N and M230L), and presented with high-level resistance to lamivudine (3TC) and emtricitabine (FTC) with M184V, intermediate-level resistance to zidovudine (AZT) and stavudine (D4T) with T215Y, and intermediate or high-level resistance to all NNRTIs with K103N and M230L.

Table: M230L/I

Table: M230L

Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial.

PMID: 28382208 2017 SAGE open medicine

Abstract: The most frequently emerging etravirine resistance-associated mutations in virologic failures were Y181C, E138A, and M230L.

Result: The most frequently emerging etravirine RAMs (developing in >=5 VFs) were Y181C (18/49), E138A (5/49), and M230L (5/49).

Discussion: The most frequently emerging etravirine RAMs, Y181C, E138A, and M230L (>=5 VFs) have also been observed previously in patients with VF in etravirine trials, as has the only other NNRTI RAM that emerged in >=5 VFs, H221Y.

High level of HIV-1 drug resistance mutations in patients with unsuppressed viral loads in rural northern South Africa.

PMID: 28750647 2017 AIDS research and therapy

Result: M230L which causes high level resistance to the entire NNRTI class, occurred in a single case.

Browser Board

Co-occurred Entities

Filtrator